Compare ARVN & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | IRWD |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 741.8M |
| IPO Year | 2018 | 2009 |
| Metric | ARVN | IRWD |
|---|---|---|
| Price | $13.49 | $3.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 5 |
| Target Price | ★ $15.57 | $4.94 |
| AVG Volume (30 Days) | 743.8K | ★ 2.9M |
| Earning Date | 05-27-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 58.84 | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | $262,600,000.00 | ★ $298,276,000.00 |
| Revenue This Year | N/A | $41.42 |
| Revenue Next Year | $1.94 | $16.01 |
| P/E Ratio | ★ N/A | $22.77 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $5.90 | $0.55 |
| 52 Week High | $18.93 | $5.78 |
| Indicator | ARVN | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 38.49 |
| Support Level | $11.10 | $3.15 |
| Resistance Level | $13.97 | $3.73 |
| Average True Range (ATR) | 0.83 | 0.38 |
| MACD | 0.10 | -0.14 |
| Stochastic Oscillator | 81.83 | 31.95 |
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.